Mingchen Health Co Ltd Class A (002919) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Mingchen Health Co Ltd Class A stock ¥2.06, price ¥18.36, that is 88.8% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range ¥9.80 – ¥39.97 · fair‑value band ¥1.55 – ¥2.67 · the ¥18.36 price screens above the ¥2.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 12, 2026.
Follow Mingchen Health Co Ltd Class A in your weekly email
Every Wednesday you see whether Mingchen Health Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mingchen Health Co.,Ltd. engages in the development, production, and sale of personal health care products in China. The company operate through Daily Chemical Products and Online game segments.
Show moreShow less
It offers skin care, shampoo, hair care, bath products and styling products under the Dihua Zhixiu, DIFASO, SunShine Fruit Oil, Mei Wang, First Collection, Golden Lion, Likoujian, High Tech Health, Green Effect, Yicai, Xiao Qiqi, and Fice brands.
In addition, the company offers online game operation services. Mingchen Health Co.,Ltd. was founded in 1994 and is based in Shantou, China.
Stock analysis
Mingchen Health Co Ltd Class A (002919) currently trades at ¥18.36, while our model-based Fair Value estimate is ¥2.06, 89% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥2.33 per share, and 0 of the 24 models we run sit above the ¥18.36 price.
Bear case: the Dividend Discount group reads lowest at ¥0.7000, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥1.55 (bear) to ¥2.67 (bull), the price of ¥18.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Mingchen Health Co Ltd Class A reported revenue of 1.5B CNY in FY2025 versus 744M CNY in FY2021, a compound +19.4%/yr. Reported net income was 28.3M CNY in FY2025, compounding −32.1%/yr from FY2021.
Key figures
Market cap 4.9B CNY (≈ $734M) Small · P/S ratio 2.50 · EPS (TTM) ¥−0.0700 · Dividend yield 0.3% · Net margin −1.1% · Return on equity −2.6% · Return on assets (EBIT) 4.3% (5-year average) · Operating margin −2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −30% fair-value upside, at −89%, 002919 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.6700 to ¥9.19). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥1.55Fair Value ¥2.06Bull¥2.67
Price ¥18.36 · Downside -88.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2020 (pandemic). Over 10 years: +9.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−22.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.7%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−22.7% vs −7.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 2%
Compare Mingchen Health Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 242 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−88.8% · Bottom 25%
Profitability
Return on assets2.2% · Below median
Net margin (12 months)−1.1% · Bottom 25%
Operating margin (12 months)−2.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)36.6% · Top 25%
Dividend yield (12 months)0.3% · Bottom 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B6.06× · Priciest 25%
P/S (12 months)2.88× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 32
FUTURE (revenue growth)100· sector 19
PAST (return on equity)0· sector 28
HEALTH (low debt)0· sector 98
DIVIDEND (yield)5· sector 51
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Mingchen Health Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/002919
Frequently asked questions
Is Mingchen Health Co Ltd Class A (002919) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ¥2.06 versus a price of ¥18.36, about 89% lower (overvalued).
What is the fair value of 002919?
Our model-based fair value for Mingchen Health Co Ltd Class A is ¥2.06 (as of Nov 12, 2026), built from audited fundamentals. The current price: ¥18.36.
What is the quality score of 002919?
Mingchen Health Co Ltd Class A has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mingchen Health Co Ltd Class A (002919)?
Our model-based price target is the fair value of ¥2.06 (as of Nov 12, 2026) from 24 valuation models. Cautious scenario ¥1.55, optimistic scenario ¥2.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Mingchen Health Co Ltd Class A stock forecast for 2026?
Our models put fair value at ¥2.06, about 89% lower versus a price of ¥18.36 (overvalued). Cautious scenario ¥1.55, optimistic scenario ¥2.67. The calculation is refreshed regularly with new filings.
What is the revenue of Mingchen Health Co Ltd Class A (002919)?
Mingchen Health Co Ltd Class A reported trailing-twelve-month revenue of about 1.7B CNY (latest available figure, as of Nov 12, 2026).
Does Mingchen Health Co Ltd Class A pay a dividend?
Mingchen Health Co Ltd Class A currently shows a dividend yield of 0.27% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Mingchen Health Co Ltd Class A (002919) and when is the ex-dividend date?
Mingchen Health Co Ltd Class A pays a dividend of ¥0.05 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Jun 9, 2026. The payout ratio is 47.0% of earnings. Free cash flow covers the dividend 0.09 times. Our assessment: Token dividend. At a yield of 0.3% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.3% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Mingchen Health Co Ltd Class A (002919)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mingchen Health Co Ltd Class A it is ¥2.06 per share (as of Nov 12, 2026), against a price of ¥18.36. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Mingchen Health Co Ltd Class A stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 002919 trades above its calculated fair value: price ¥18.36, fair value ¥2.06, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002919?
No. The price is what the market pays today (¥18.36); the fair value is what the company's own numbers justify (¥2.06). For Mingchen Health Co Ltd Class A the two are ¥16.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mingchen Health Co Ltd Class A worth?
The market values Mingchen Health Co Ltd Class A at about 4.9B CNY (market capitalisation, as of Nov 12, 2026). Per share that is ¥18.36; our models calculate a fair value of ¥2.06 per share.
What do the bullish and bearish scenarios say about 002919?
Our models span a range for Mingchen Health Co Ltd Class A: cautious scenario ¥1.55, base ¥2.06, optimistic ¥2.67 per share (as of Nov 12, 2026, price ¥18.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mingchen Health Co Ltd Class A (002919)?
Balance-sheet figures for Mingchen Health Co Ltd Class A (as of Nov 12, 2026): return on equity −2.6%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 002919 from its 52-week high?
Mingchen Health Co Ltd Class A trades at ¥18.36, about 34% below its 52-week high of ¥27.77 and 23% above the low of ¥14.87 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.06 is for.
Which stocks are comparable to Mingchen Health Co Ltd Class A?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mingchen Health Co Ltd Class A stock attractive at the current price?
The data as of Nov 12, 2026: price ¥18.36, calculated fair value ¥2.06 (−89%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002919 calculated?
We run Mingchen Health Co Ltd Class A through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥2.06 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Mingchen Health Co Ltd Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mingchen Health Co Ltd Class A (002919)?
The closing price on Nov 11, 2026 was ¥18.36. Our model-based fair value is ¥2.06, about 89% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mingchen Health Co Ltd Class A right now?
The price sits above even our optimistic bull case (¥2.67). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Mingchen Health Co Ltd Class A
How large is the market capitalisation of Mingchen Health Co Ltd Class A (002919)?
The market capitalisation of Mingchen Health Co Ltd Class A is 4.9B CNY (≈ $734M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mingchen Health Co Ltd Class A (002919)?
The price-to-sales ratio of Mingchen Health Co Ltd Class A is 2.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mingchen Health Co Ltd Class A (002919)?
Earnings per share at Mingchen Health Co Ltd Class A are ¥−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Mingchen Health Co Ltd Class A (002919)?
The dividend yield of Mingchen Health Co Ltd Class A is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Mingchen Health Co Ltd Class A (002919)?
The net margin of Mingchen Health Co Ltd Class A is −1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Mingchen Health Co Ltd Class A (002919)?
The return on equity (ROE) of Mingchen Health Co Ltd Class A is −2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mingchen Health Co Ltd Class A (002919)?
On an EBIT basis the return on assets of Mingchen Health Co Ltd Class A is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mingchen Health Co Ltd Class A (002919)?
The operating margin of Mingchen Health Co Ltd Class A is −2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mingchen Health Co Ltd Class A (002919)?
Revenue at Mingchen Health Co Ltd Class A is growing +36.6% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mingchen Health Co Ltd Class A (002919)?
Earnings per share at Mingchen Health Co Ltd Class A are growing −27.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mingchen Health Co Ltd Class A (002919) generate?
The free cash flow of Mingchen Health Co Ltd Class A is 1.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Mingchen Health Co Ltd Class A (002919) hold?
Mingchen Health Co Ltd Class A holds more cash than debt, 150M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Mingchen Health Co Ltd Class A in the live analysis
One click puts Mingchen Health Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 12, 2026